FDA’s Wednesday announcement it has narrowed its authorizations for COVID-19 vaccines, rescinding emergency use authorizations (EUAs) and limiting full approvals to certain high-risk populations marks a major shift in the federal government’s approach to COVID-19 vaccination and has immediate implications for medical providers, particularly physicians and pharmacists, who must now navigate new eligibility rules and potential liability risks when administering vaccines.